NasdaqCM:TMDI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Titan Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TMDI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.9%

TMDI

-3.3%

US Medical Equipment

-3.3%

US Market


1 Year Return

-38.5%

TMDI

13.7%

US Medical Equipment

10.9%

US Market

Return vs Industry: TMDI underperformed the US Medical Equipment industry which returned 14.7% over the past year.

Return vs Market: TMDI underperformed the US Market which returned 13.1% over the past year.


Shareholder returns

TMDIIndustryMarket
7 Day2.9%-3.3%-3.3%
30 Day-11.8%-2.5%-5.7%
90 Day-20.8%12.2%8.2%
1 Year-38.5%-38.5%14.7%13.7%13.4%10.9%
3 Year-91.3%-91.3%69.0%64.7%34.9%25.9%
5 Year-97.8%-97.8%140.9%122.6%84.6%63.8%

Price Volatility Vs. Market

How volatile is Titan Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Titan Medical undervalued compared to its fair value and its price relative to the market?

25.07x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TMDI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TMDI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TMDI is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: TMDI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TMDI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TMDI is overvalued based on its PB Ratio (25.1x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Titan Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Titan Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Titan Medical performed over the past 5 years?

0.04%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TMDI is currently unprofitable.

Growing Profit Margin: TMDI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TMDI is unprofitable, but has reduced losses over the past 5 years at a rate of 0.04% per year.

Accelerating Growth: Unable to compare TMDI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TMDI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: TMDI has a negative Return on Equity (-50.99%), as it is currently unprofitable.


Next Steps

Financial Health

How is Titan Medical's financial position?


Financial Position Analysis

Short Term Liabilities: TMDI's short term assets ($30.2M) exceed its short term liabilities ($28.2M).

Long Term Liabilities: TMDI's short term assets ($30.2M) exceed its long term liabilities ($2.0M).


Debt to Equity History and Analysis

Debt Level: TMDI's debt to equity ratio (79.4%) is considered high.

Reducing Debt: Insufficient data to determine if TMDI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TMDI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TMDI has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 12.4% each year.


Next Steps

Dividend

What is Titan Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TMDI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TMDI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TMDI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TMDI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TMDI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

David McNally (58 yo)

3.67yrs

Tenure

US$495,000

Compensation

Mr. David J. McNally has been Chief Executive Officer at Titan Medical Inc. since January 3, 2017 and has been its President since January 9, 2017 and also serves as its Chairman since June, 2020. Mr. McNa ...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD495.00K) is about average for companies of similar size in the US market ($USD601.34K).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
David McNally
President3.67yrsUS$495.00k0.0051%
$ 2.9k
Stephen Randall
CFO & Director2.83yrsUS$313.20k0.028%
$ 15.9k
Sachin Sankholkar
Vice President of Marketingno dataUS$230.00k0.00082%
$ 462.1
Bruce Wolff
Senior Advisor & Member of Surgeon Advisory Boardno dataUS$8.02kno data
Perry Genova
Senior Vice President of Research & Development3yrsUS$375.00k0.00063%
$ 355.1
Jasminder Brar
VP of Legal0.25yrUS$203.84kno data
Monique Delorme
Vice President of Financeno datano data0.040%
$ 22.4k

3.0yrs

Average Tenure

Experienced Management: TMDI's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David McNally
President3.67yrsUS$495.00k0.0051%
$ 2.9k
Stephen Randall
CFO & Director2.83yrsUS$313.20k0.028%
$ 15.9k
Bruce Wolff
Senior Advisor & Member of Surgeon Advisory Boardno dataUS$8.02kno data
John Barker
Independent Director11.33yrsUS$67.00k0.056%
$ 31.6k
Lee Swanstrom
Member of Surgeon Advisory Boardno datano datano data
John Valvo
Member of Surgeon Advisory Board10.08yrsno datano data
Arnold Advincula
Member of Surgeon Advisory Board6.67yrsno datano data
Eduardo Parra-Davilla
Member of Surgeon Advisory Boardno datano datano data
Phillip McStotts
Independent Director0.25yrno data0.012%
$ 6.9k

4.8yrs

Average Tenure

62yo

Average Age

Experienced Board: TMDI's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TMDI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 142.9%.


Top Shareholders

Company Information

Titan Medical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Titan Medical Inc.
  • Ticker: TMDI
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$75.002m
  • Listing Market Cap: CA$56.359m
  • Shares outstanding: 81.52m
  • Website: https://www.titanmedicalinc.com

Number of Employees


Location

  • Titan Medical Inc.
  • 155 University Avenue
  • Suite 750
  • Toronto
  • Ontario
  • M5H 3B7
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TMDTSX (The Toronto Stock Exchange)YesCommon SharesCACADJul 2008
TMDINasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJul 2008
QTNADB (Deutsche Boerse AG)YesCommon SharesDEEURJul 2008

Biography

Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invas ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/24 08:02
End of Day Share Price2020/09/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.